Pneumonia, Pneumococcal - Pipeline Insight, 2024

This Pneumonia, Pneumococcal - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Pneumonia, Pneumococcal pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pneumonia, Pneumococcal Understanding

Pneumonia, Pneumococcal: Overview

Pneumococcal infections are caused by Streptococcus pneumoniae, a gram-positive, catalase-negative organism commonly referred to as pneumococcus. The bacteria spread through contact with people who are ill or by healthy people who carry the bacteria in the back of their nose. Pneumococcal infections can be mild or severe. Symptoms of pneumococcal infections vary depending on the site of the infection. Most pneumococcal infections occur in the Lungs (pneumonia), Middle ear (otitis media, which is common among children), Sinuses (sinusitis) Pneumococcal infections usually fall into one of two categories: non-invasive pneumococcal infections - these occur outside the major organs or the blood and tend to be less serious and invasive pneumococcal infections - these occur inside a major organ or the blood and tend to be more serious. People with a weakened immune system are most at risk of catching a pneumococcal infection. Diagnosis is based on the physical exam and medical history. Treatment is with antibiotics and vaccines that can prevent pneumococcal infections.

Pneumonia, Pneumococcal - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumonia, Pneumococcal pipeline landscape is provided which includes the disease overview and Pneumonia, Pneumococcal treatment guidelines. The assessment part of the report embraces, in depth Pneumonia, Pneumococcal commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumonia, Pneumococcal collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pneumonia, Pneumococcal R&D. The therapies under development are focused on novel approaches to treat/improve Pneumonia, Pneumococcal.

This segment of the Pneumonia, Pneumococcal report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pneumonia, Pneumococcal Drugs
V116: Merck & CoV116, the company’s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. V116 is designed to specifically target serotypes that are responsible for 85 percent of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 20191. Importantly, the eight serotypes in V116 that are not included in any currently-licensed pneumococcal vaccine account for over 30 percent of this disease burden alone.

Pneumonia, Pneumococcal: Therapeutic Assessment

This segment of the report provides insights about the Pneumonia, Pneumococcal drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pneumonia, Pneumococcal

There are approx. 12+ key companies which are developing the therapies for Pneumonia, Pneumococcal. The companies which have their Pneumonia, Pneumococcal drug candidates in the most advanced stage, i.e. Phase III include Merck & Co.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pneumonia, Pneumococcal pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pneumonia, Pneumococcal: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumonia, Pneumococcal therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumonia, Pneumococcal drugs.

Pneumonia, Pneumococcal Report Insights

• Pneumonia, Pneumococcal Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pneumonia, Pneumococcal Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pneumonia, Pneumococcal drugs?
• How many Pneumonia, Pneumococcal drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumonia, Pneumococcal?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pneumonia, Pneumococcal therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pneumonia, Pneumococcal and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vaxcyte
• Merck & Co
• Affinivax
• GlaxoSmithKline
• Pfizer
• EuBiologics

Key Products

• V116
• AFX3772
• MAPS30
• VAX-24
• Pneumococcal vaccine
• PF 06842433
• Pneumococcal conjugate vaccine

This product will be delivered within 2 business days.